Jazz Pharmaceuticals plc

NasdaqGS:JAZZ Stock Report

Market Cap: US$7.3b

Jazz Pharmaceuticals Valuation

Is JAZZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of JAZZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$708.90
Fair Value
83.1% undervalued intrinsic discount
19
Number of Analysts

Below Fair Value: JAZZ ($120.07) is trading below our estimate of fair value ($708.9)

Significantly Below Fair Value: JAZZ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JAZZ?

Key metric: As JAZZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for JAZZ. This is calculated by dividing JAZZ's market cap by their current earnings.
What is JAZZ's PE Ratio?
PE Ratio15.7x
EarningsUS$463.16m
Market CapUS$7.35b

Price to Earnings Ratio vs Peers

How does JAZZ's PE Ratio compare to its peers?

The above table shows the PE ratio for JAZZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.7x
CORT Corcept Therapeutics
50.7x37.1%US$7.2b
ELAN Elanco Animal Health
28.9x1.6%US$5.9b
OGN Organon
2.9x-8.3%US$3.9b
PBH Prestige Consumer Healthcare
20.2x4.8%US$3.8b
JAZZ Jazz Pharmaceuticals
15.7x12.3%US$7.3b

Price-To-Earnings vs Peers: JAZZ is good value based on its Price-To-Earnings Ratio (15.7x) compared to the peer average (25.7x).

Price to Earnings Ratio vs Industry

How does JAZZ's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
2.9x-8.3%US$3.94b
NDOI Endo
0.7xn/aUS$2.18b
PROC.F Procaps Group
2.4xn/aUS$130.88m
KPRX Kiora Pharmaceuticals
2x0.2%US$11.37m
JAZZ 15.7xIndustry Avg. 18.7xNo. of Companies8PE01224364860+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: JAZZ is good value based on its Price-To-Earnings Ratio (15.7x) compared to the US Pharmaceuticals industry average (18.7x).

Price to Earnings Ratio vs Fair Ratio

What is JAZZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JAZZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.7x
Fair PE Ratio23.2x

Price-To-Earnings vs Fair Ratio: JAZZ is good value based on its Price-To-Earnings Ratio (15.7x) compared to the estimated Fair Price-To-Earnings Ratio (23.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst JAZZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$120.07
US$180.95
+50.7%
15.7%US$230.00US$128.00n/a19
Jan ’26US$123.15
US$181.05
+47.0%
15.8%US$230.00US$128.00n/a19
Dec ’25US$121.59
US$177.53
+46.0%
16.4%US$230.00US$128.00n/a19
Nov ’25US$110.45
US$179.39
+62.4%
16.5%US$230.00US$120.00n/a18
Oct ’25US$109.04
US$178.78
+64.0%
16.8%US$230.00US$120.00n/a18
Sep ’25US$115.98
US$175.63
+51.4%
18.1%US$230.00US$120.00n/a19
Aug ’25US$114.38
US$175.00
+53.0%
18.2%US$230.00US$113.00n/a19
Jul ’25US$106.47
US$179.16
+68.3%
16.2%US$230.00US$117.00n/a19
Jun ’25US$105.25
US$180.89
+71.9%
16.7%US$230.00US$117.00n/a18
May ’25US$110.31
US$188.21
+70.6%
15.6%US$230.00US$121.00n/a20
Apr ’25US$118.98
US$188.76
+58.6%
14.9%US$230.00US$131.00n/a20
Mar ’25US$118.85
US$186.89
+57.3%
15.6%US$230.00US$131.00n/a19
Feb ’25US$123.68
US$188.05
+52.0%
16.0%US$235.00US$135.00US$124.3719
Jan ’25US$123.00
US$190.94
+55.2%
15.8%US$240.00US$135.00US$123.1518
Dec ’24US$119.11
US$193.00
+62.0%
14.6%US$240.00US$135.00US$121.5918
Nov ’24US$127.34
US$199.00
+56.3%
11.9%US$240.00US$140.00US$110.4518
Oct ’24US$129.44
US$200.24
+54.7%
12.0%US$240.00US$140.00US$109.0417
Sep ’24US$143.76
US$200.24
+39.3%
12.0%US$240.00US$140.00US$115.9817
Aug ’24US$129.54
US$200.53
+54.8%
11.6%US$240.00US$140.00US$114.3817
Jul ’24US$123.97
US$199.75
+61.1%
12.0%US$240.00US$140.00US$106.4716
Jun ’24US$129.12
US$200.67
+55.4%
9.3%US$240.00US$165.00US$105.2518
May ’24US$141.37
US$201.72
+42.7%
8.0%US$240.00US$180.00US$110.3118
Apr ’24US$146.33
US$202.28
+38.2%
7.6%US$240.00US$180.00US$118.9818
Mar ’24US$140.51
US$200.63
+42.8%
7.9%US$240.00US$180.00US$118.8519
Feb ’24US$157.77
US$200.63
+27.2%
7.9%US$240.00US$180.00US$123.6819
Analyst Price Target
Consensus Narrative from 19 Analysts
US$180.95
Fair Value
33.6% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 22:58
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jazz Pharmaceuticals plc is covered by 51 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Ishan MajumdarBaptista Research
Richard SilverBarclays